Acrivon Therapeutics Announces Initial Clinical Data for Novel WEE1/PKMYT1 Inhibitor ACR-2316
Reuters
Oct 23
Acrivon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initial Clinical Data for Novel WEE1/PKMYT1 Inhibitor ACR-2316
Acrivon Therapeutics Inc. has announced upcoming presentations of preclinical and initial clinical data for its novel candidate ACR-2316 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, MA. The data will highlight the company's proprietary Generative Phosphoproteomics AP3 platform, including the AP3 KaiSR ensemble model, which is used to optimize drug design for specific pathway effects in tumor cells. Preclinical results have demonstrated differentiated and superior pathway effects of ACR-2316 compared to benchmark WEE1 and PKMYT1 inhibitors. Initial clinical data from the ongoing Phase 1 study, including observed clinical activity and a confirmed partial response during dose escalation in AP3-predicted solid tumor types, will be reported later this year. The posters will be available on Acrivon's website following their presentation at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550454-en) on October 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.